TL1A blockers enter the IBD pipeline — what the phase 2 trial data show so far.
Saudi Journal of GastroenterologySaudi J Gastroenterol. 2026; 32(5); pp. 379-393
Jeong-Gyu Choi, Eun Jeong Gong, Chang Seok Bang, et al.
SGA Briefing
A systematic review surveying phase 2 clinical trial data on TL1A-targeting drugs, an emerging class of biologics being tested for inflammatory bowel disease.
Read the full article
This links to the publisher’s open-access copy of record. A self-hosted PDF will appear here once one is on file.